VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
NUTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
NUTXNutex Health, Inc.
$212.31$1.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksNUTXBalance Sheet

Nutex Health, Inc. (NUTX) Balance Sheet

13Y historyFree accessUpdated daily

The balance sheet has strengthened significantly, with equity rising from $63.0M to $507.3M and D/E improving from 3.40 to 0.51, but retained earnings remain negative at -$173.5M, indicating reliance on external capital.

Income StatementBalance SheetCash FlowRatios

NUTX Balance Sheet

Annual statement

NUTX Balance Sheet

Nutex Health, Inc. (NUTX) balance sheet — 13-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'11Dec'10
Total Current Assets585.65M538.81M292.48M90.85M97.97M154.02M135.51M45.74M305.42K55.08K507.93K7.63M1.76M2.22M
Cash & Short-Term Investments205.21M185.57M43.58M22M34.26M36.12M25.51M8M119.27K9.45K10.52K122.29K224.8K465.55K
Cash Only205.21M185.57M43.58M22M34.26M36.12M25.51M8M119.27K9.45K10.52K122.29K224.8K465.55K
Short-Term Investments00000000000000
Accounts Receivable351.68M325.42M236.05M62.78M58.32M114.76M108.14M36.14M186.15K6.25K15K0720.87K613.65K
Days Sales Outstanding151.31135.71179.5292.5297.06126.34144.04135.91743.642.55--103.24176.87
Inventory4.21M2.87M2.85M3.39M3.53M2.81M1.73M899.91K27.07K00000
Days Inventory Outstanding3.32.433.675.816.336.755.41-158.62-----
Other Current Assets24.56M24.95M10M2.68M1.87M323.28K00-27.07K39.38K482.41K7.27M754.77K812.73K
Total Non-Current Assets378.98M379.71M362.84M307.4M333.78M240.63M173.05M133.48M144.01K3.27M2.9K3.38K313.77K116.11K
Property, Plant & Equipment340.92M343.9M324.69M269.39M295.15M238.36M170.81M131.28M7.61K3.85K1.18K1.66K18.56K5.09K
Fixed Asset Turnover2.49x2.55x1.48x0.92x0.74x1.39x1.60x0.74x12.00x13.95x--137.30x248.94x
Goodwill13.92M13.92M13.92M17.07M17.01M1.14M1.14M3.47M0000111.03K111.03K
Intangible Assets20.58M21.23M15.53M20.51M21.19M682.65K01.54M2.57M3.27M0000
Long-Term Investments0000000100K116.96K00000
Other Non-Current Assets3.56M662K711.35K431.13K423.43K456.08K1.1M-2.81M19.43K1.95K1.72K1.72K00
Total Assets964.63M918.52M655.32M398.25M431.75M394.65M308.55M179.22M449.43K3.33M510.83K7.64M2.07M2.33M
Asset Turnover0.89x0.95x0.73x0.62x0.51x0.84x0.89x0.54x0.20x0.02x--1.23x0.54x
Asset Growth %200.47%40.16%64.55%-7.76%9.4%27.9%72.16%39778.36%-86.5%551.63%-93.31%268.48%-11.2%-
Total Current Liabilities117.22M157.91M140.87M58.31M54.86M37.69M31.45M72.13M1.04M959.78K6.38M6.08M288.58K351.62K
Accounts Payable4.28M48.97M13.96M25.28M23.93M17.65M8.63M1.75M567.01K348.35K356K168.97K263.19K326.23K
Days Payables Outstanding33.8741.4717.9643.3542.8442.3227.06-3.32K225.3274.72K93.16K62.81152.04
Short-Term Debt18M14.08M17.95M14.18M15.17M10.23M18.65M13.35M477.06K386.19K50K000
Deferred Revenue (Current)00000173.92K38.65K165.56K9.19K9.1K0811.23K00
Other Current Liabilities99.22M8.26M005.61M3.6M-38.65K3.37M332.19K216.14K5.97M5.1M25.39K25.39K
Current Ratio5.00x3.41x2.08x1.56x1.79x4.09x4.31x0.63x0.29x0.06x0.08x1.26x6.10x6.31x
Quick Ratio4.96x3.39x2.06x1.50x1.72x4.01x4.25x0.62x0.27x0.06x0.08x1.26x6.10x6.31x
Cash Conversion Cycle120.7496.66165.2254.9960.5590.77122.39--2.42K-----
Total Non-Current Liabilities340.1M337.18M312.56M260.83M256.56M165.38M129.73M56.26M902.72K000181.69K0
Long-Term Debt298.13M29.17M22.47M26.31M23.05M78.82M81.9M40.88M902.72K00000
Capital Lease Obligations897.83M298.91M290.1M229.37M223.06M86.56M47.83M15.38M000000
Deferred Tax Liabilities43.06M9.09M05.15M10.45M1.75M00000000
Other Non-Current Liabilities31.11M0000-1.75M000000181.69K0
Total Liabilities457.32M495.09M453.43M319.14M311.42M203.07M161.19M128.39M1.95M959.78K6.38M6.08M470.27K351.62K
Total Debt316.13M351.39M340.3M275.76M267.2M178.55M150.12M119.94M1.38M386.19K50K000
Net Debt110.92M165.82M296.72M253.75M232.95M142.43M124.61M111.94M1.26M376.74K39.48K-122.29K-224.8K-465.55K
Debt / Equity0.51x0.83x1.69x3.49x2.22x0.93x1.02x2.36x-0.16x----
Debt / EBITDA0.82x1.19x2.27x--1.00x0.94x3.23x------
Net Debt / EBITDA0.29x0.56x1.98x--0.80x0.78x3.01x------
Interest Coverage12.21x12.01x6.51x-1.97x-32.60x28.35x23.66x10.09x-1.31x-15.35x-173.90x-169.42x--
Total Equity620.31M423.44M201.89M79.11M120.33M191.58M147.37M50.84M-1.5M2.37M-5.87M1.56M1.6M1.99M
Equity Growth %703.75%109.73%155.22%-34.26%-37.19%30%189.89%3495.03%-163.21%140.36%-475.93%-2.58%-19.27%-
Book Value per Share86.4262.6739.5917.9428.4348.4834.3412.28-0.210.57-2.840.761.341.66
Total Shareholders' Equity507.31M329.45M146.34M61.45M95.86M114.65M85.81M28.31M-1.5M2.37M-5.87M1.56M1.6M1.99M
Common Stock7K7K5.51K676.68K650.22K592.79K5.28K4.65K1.77K126.2K39.71K39.68K00
Retained Earnings-173.54M-286.19M-356.89M-409.07M-363.29M102.32M-18.22M-12.57M-5.45M-9.65M-10.23M-2.8M-824.45K-441.06K
Treasury Stock000000000-1M0000
Accumulated OCI00000000000000
Minority Interest113M93.99M55.55M17.65M24.46M76.93M61.56M22.53M000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStable
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Negative SBC and revenue volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Balance Sheet Strengthens Rapidly

Nutex Health's equity surged from $63.0M in 2024Q1 to $507.3M in 2026Q2, while total debt fell from $272.4M to $316.1M, per recent SEC filings, indicating a marked deleveraging trend.

The equity expansion is driven by a combination of retained earnings improvement (from -$409.4M to -$173.5M) and likely capital raises, as total assets grew 138% over the period. This suggests the company is transitioning from a highly leveraged, loss-making entity to a more solvent one, though the pace of asset growth warrants scrutiny for acquisition-driven expansion.

Leverage Declines as Debt Stabilizes

D/E ratio improved from 3.40 in 2024Q1 to 0.51 in 2026Q2, with total debt peaking at $389.0M in 2025Q3 before declining to $316.1M, as reported in financial statements, signaling reduced financial risk.

The absolute debt level remains substantial at $316.1M, but the equity base has grown faster, lowering leverage. The reduction in debt from the 2025Q3 peak suggests either debt repayment or conversion, which may indicate improved cash generation or refinancing. Investors should monitor the composition of debt, as the data does not distinguish between short-term and long-term maturities, which could pose refinancing risk if credit conditions tighten.

Asset Mix Shifts Toward Cash and PPE

Cash and PPE grew to $205.2M and $340.9M respectively by 2026Q2, while goodwill remained flat at $13.9M, based on balance sheet data, indicating a tangible asset-heavy expansion.

The increase in PPE from $266.1M to $340.9M suggests significant investment in physical facilities, consistent with a care facilities operator. Goodwill is minimal relative to total assets, reducing impairment risk. The rising cash balance provides a buffer, but the asset growth may be tied to acquisitions, as total assets jumped from $404.3M to $964.6M, which could introduce integration risks.

Equity Quality Improves but Retained Deficit Persists

Retained earnings improved from -$409.4M to -$173.5M over ten quarters, yet remain negative, while equity reached $507.3M, per reported figures, suggesting reliance on external capital rather than organic profitability.

The narrowing deficit indicates improving profitability, but the negative retained earnings imply that the company has not yet generated cumulative profits. The equity growth likely stems from capital raises, as evidenced by the cash balance increase. Stock-based compensation has been negative in some quarters, which may distort equity quality; investors should assess the sustainability of this improvement.

Liquidity Buffer Strengthens Significantly

Current ratio improved from 1.68 in 2024Q1 to 5.00 in 2026Q2, with cash rising from $30.0M to $205.2M, as per balance sheet data, providing a robust cushion against short-term obligations.

The current ratio of 5.00 indicates ample liquidity, far exceeding the peer average of around 1.80. Cash alone covers a substantial portion of total debt, suggesting low near-term solvency risk. However, the high cash balance may be inefficient if not deployed for growth, and the company's operating cash flow volatility could still pose challenges in covering debt service if cash is used for acquisitions or dividends.

Negative SBC Distorts Equity and Cash Flow

Stock-based compensation was negative in several quarters, including -$78.7M in 2025Q2, which may inflate reported operating cash flow and understate equity dilution, based on cash flow statement data, warranting closer scrutiny.

The negative SBC is unusual and could indicate reversals of prior accruals or accounting adjustments, potentially masking true employee compensation costs. This distortion affects both equity quality and cash flow metrics, as operating cash flow may be overstated. Investors should adjust for these non-cash items to assess the company's true earnings power and cash generation sustainability.

NUTX — Frequently Asked Questions

Quick answers to the most common questions about buying NUTX stock.

What are the total assets of Nutex Health, Inc. (NUTX)?

As of 2025, Nutex Health, Inc. (NUTX) had total assets of $918.5M including $538.8M in current assets.

How much debt does Nutex Health, Inc. (NUTX) have?

Nutex Health, Inc. (NUTX) carries total debt of $351.4M, offset by $185.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Nutex Health, Inc.?

Nutex Health, Inc. (NUTX) has total shareholders' equity (book value) of $329.4M ($62.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Nutex Health, Inc.'s current ratio and liquidity?

Nutex Health, Inc. (NUTX) reported a current ratio of 3.41x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.